Medical news today: Monday, November 2, 2026
England rolls out a child early-warning score in A&E, Caregen shares sink after an FDA supplement limit, and Brazil sends more mpox vaccine to Rio
Get tomorrow's issue in your inbox.
- 01
FDA approves generic HIV prevention shot, widening access for lower-income countries
Source: STAT
STAT reports: The FDA has approved a generic HIV prevention shot, a key step in widening access for dozens of lower-income countries.
Why it mattersSTAT reports the approval is a key step in getting the long-acting prevention shot to dozens of lower-income countries. More on Approvals & regulatory →
- 02
Novartis heart drug fails, leaving doctors seeking proof for a genetic cholesterol target
Source: Reuters
Why it mattersThe failure leaves open whether lowering this genetically driven cholesterol target helps patients, so doctors are still waiting for evidence.
- 03
Teva halts mid-stage study in a neurodegenerative disorder
Source: Reuters
Why it mattersStopping a mid-stage trial removes one experimental option from the pipeline for patients with this neurodegenerative disorder. More on Drug & device safety →
- 04
Kymera nears eczema trial readout in bid to rival Dupixent (STAT+, paywall)
Source: STAT
STAT reports: Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.
Why it mattersInvestors and doctors are waiting on mid-stage results for an experimental Kymera therapy that is positioned as a challenger to Dupixent in eczema. More on Markets →
Market news · Not investment advice
- 05
STAT finds mitochondrial IVF technique marketed to older women with little evidence
Source: STAT
STAT reports: Pioneering IVF technique to reduce the risk of children inheriting mitochondrial diseases is being marketed as a fertility procedure for older women, despite little evidence it works.
Why it mattersSTAT reports an IVF technique built to reduce inherited mitochondrial disease is being sold as a fertility procedure for older women, despite little evidence it works for that.
- 06
Sanofi expects Dupixent to gain most from Lilly’s Ebglyss ad push
Source: Fierce Pharma
Why it mattersSanofi says rival eczema ads raise awareness that mostly benefits Dupixent, the market leader, with only about 20% of atopic dermatitis patients on advanced therapies. Dupixent sales grew almost 35% to €5.7 billion in the third quarter, while Ebglyss sales rose 59% to $202 million. More on Pharma industry →
- 07
CDSCO pulls FatX registration, rules it a drug, not a cosmetic
Source: Business Standard
Why it mattersIndia's drug regulator cancelled FatX's registration over misleading claims, treating it as a drug rather than a cosmetic, which sets a line for products sold as cosmetics. More on Approvals & regulatory →
- 08
Pennsylvania measles outbreak reaches 1,426 cases in 44 counties
Source: Pennsylvania Department of Health
Pennsylvania's health department says 1,426 measles cases have been confirmed across 44 counties so far in 2026, with a CDC team helping its response. State staff have given more than 6,800 MMR vaccinations at 237 pop-up clinics since the outbreak began in late April.
Why it mattersMeasles spreads very easily and can be deadly; the department notes two doses of MMR vaccine are 97% effective, so checking family vaccine records is the key step. More on Infectious disease →
- 09
365 Whole Foods Market ashwagandha capsules recalled over Salmonella risk
Source: FDA (company announcement)
Vitality Works is recalling one lot (2025-26227, expiry 10/13/2028) of 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha Capsules, 120 count, sold at Whole Foods stores nationwide and on Amazon.com from 24 November 2025 to 20 October 2026. Routine sampling flagged possible Salmonella; no illnesses have been reported, the company says.
Why it mattersAshwagandha is a popular herbal supplement; anyone with this lot should not take it and can get a refund at Whole Foods, as Salmonella is most dangerous for children, older people and those with weak immunity. More on Drug & device safety →
- 10
Big study names blood protein TSP2 as best single test for fatty liver scarring
Source: University Medical Center Mainz
The European LITMUS study compared more than 30 blood tests and combinations in 1,590 people with biopsy-confirmed fatty liver disease (MASLD), and found thrombospondin-2 (TSP2) the most promising single blood protein for spotting significant scarring, cirrhosis and higher-risk inflammation. No test met the target for early fatty liver without scarring, the researchers report.
Why it mattersFatty liver affects a large share of adults worldwide, and better blood tests could mean fewer invasive liver biopsies, though early disease still needs other checks. More on Pharma industry →
Market news · Not investment advice
- 11
England adds early-warning score to spot children worsening in A&E
Source: BBC News
Hospital emergency departments in England are introducing a National Paediatric Early Warning System (PEWS), which asks staff to check, log and score children's vital signs such as heart rate, blood pressure and oxygen levels. A high score means a child needs urgent attention, and worries raised by staff, parents, carers or the child trigger immediate escalation, the BBC reports.
Why it mattersParents gain a formal way to raise the alarm while waiting in busy A&E departments this winter, and other health systems facing long waits may copy the approach. More on Pharma industry →
- 12
Caregen shares hit daily limit down after FDA supplement intake cap
Source: Seoul Economic Daily (in Korean)
Shares of South Korean company Caregen fell 29.86% to 23,250 won by 9:03 am in Seoul on 2 November, hitting the day's lower limit, the paper reported. The drop followed reports that the US FDA limited how long its weight-management supplement Coglutide should be taken.
Why it mattersIt shows how fast a regulator's safety note on a supplement can wipe value off a company, a risk for investors in the booming weight-loss supplement trade. Not investment advice. More on Approvals & regulatory →
Market news · Not investment advice
- 13
Cleft lip patients turn to filler as experts call for regulation
Source: BBC Health
BBC Health reports: Two women from Wales say dermal filler for cleft lip surgery scars has boosted their confidence. The treatment is offered by the NHS and by aesthetic clinics, and practitioners and surgeons say the aesthetics industry is currently unregulated.
Why it mattersA University of the West of England researcher says adults with a cleft are being deliberately targeted by the aesthetics industry, and a cleft surgeon notes filler in some areas can rule out later revision surgery. More on Approvals & regulatory →
- 14
FDA limits Caregen's Coglutide weight supplement to 30 days of use
Source: Seoul Economic Daily
In reviewing Caregen's new dietary ingredient notification for its weight-management supplement Coglutide, the US FDA set conditions of 100 mg once daily for no more than 30 consecutive days in adults, citing abnormal findings in a 90-day rat toxicity study, the paper reports. The company's sales material recommends 8 to 12 weeks of use; the FDA did not review weight-loss efficacy.
Why it mattersShoppers buying 'GLP-1-style' weight supplements should know that an FDA filing is not a safety approval, and that labels can promise more than regulators accept. More on Approvals & regulatory →
- 15
Kenya's Nakuru enlists West Africa Ebola veterans to prepare hospitals
Source: Daily Nation
Nakuru County in Kenya has brought in health workers who fought Ebola in West Africa in 2014-15, plus COVID-19 responders, to prepare for any suspected cases along the Northern Corridor transport route, the paper reports. Langalanga and Naivasha hospitals ran training drills and are designated Ebola isolation centres.
Why it mattersWith Congo's outbreak spreading in the region, early preparation along busy truck and travel routes is how neighbouring countries try to stop cases from turning into outbreaks. More on Infectious disease →
- 16
India's cap on cancer drug margins takes effect 9 November
Source: BioSpectrum India
India has capped trade margins at 30% on 137 non-scheduled anti-cancer medicines, with revised prices due from 9 November 2026; the measure is expected to cut retail prices by up to 70% and save patients Rs 2,500 crore a year, BioSpectrum reports. The Supreme Court has asked why similar controls should not cover other medicines and devices.
Why it mattersFamilies paying for cancer treatment in India could see lower prices on many medicines from next week, and the court case may widen price controls to other drugs. More on Oncology →
- 17
Brazil sends extra mpox vaccine to Rio as city cases jump
Source: The Rio Times
Health Minister Alexandre Padilha said on 31 October that Brazil will send more mpox vaccine to Rio de Janeiro, which counted 74 cases in September and October against 10 in the same months of 2025. He said Brazil faces no national outbreak and vaccination stays limited to groups already recommended.
Why it mattersMpox (a viral infection that causes painful rashes) is rising in a major travel city before year-end crowds, so travellers and at-risk groups should watch local health advice. More on Infectious disease →
- 18
Pfizer headlines a busy week of pharma earnings with results on 3 November
Source: Finimize (citing Reuters)
Pfizer is due to report results before the US market opens on 3 November, according to Reuters' earnings diary as summarised by Finimize, during a 2-6 November week crowded with big company results.
Why it mattersBig drugmakers' results and outlooks can move pharma shares and pension funds, and often hint at drug pricing and job plans. Not investment advice. More on Pharma industry →
Market news · Not investment advice
- 19
India halts Sun Pharma eye-drug production at Assam plant over quality lapses
Source: CNA (Reuters)
India's drug regulator CDSCO and Assam's drugs controller ordered Sun Pharmaceutical Industries to stop making, selling and distributing eye medicines from its Assam plant after finding failures in its quality management system, according to documents reviewed by Reuters. The 20 August order follows Sun's July voluntary recall of about 11 eye-care brands and stays until a satisfactory compliance report is submitted.
Why it mattersEye drops must be sterile, so tighter checks protect patients, though people using affected brands may need to switch products while supply is paused. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
